• 1
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 2
    Wilson A, de Vries N, Pocioit F, di Giovine F, van de Putte L, Duff G. An allelic polymorphism in the human tumor necrosis factor α promoter region is strongly associated with HLA A1 B8 and DR3 alleles. J Exp Med 1993; 177: 55760.
  • 3
    Braun N, Michel U, Ernst B, Metzner R, Bitsch A, Weber F, et al. Gene polymorphism at position −308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett 1996; 215: 758.
  • 4
    Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumor necrosis factor gene polymorphism influences TNF alpha production in lipopolysaccharide stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 4016.
  • 5
    Schaaf B, Seitzer U, Pravica V, Aries S, Zabel P. Tumor necrosis factor alpha promoter gene polymorphism and increased tumor necrosis factor serum bioactivity in farmer's lung patients. Am J Respir Crit Care Med 2001; 163: 37982.
  • 6
    Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, et al. Low T cell production of TNF alpha and IFN gamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60: 3642.
  • 7
    De Jong B, Westendorp R, Bakker A, Huizinga T. Polymorphisms in or near tumor necrosis factor gene do not determine levels of endotoxin induced TNF production. Genes Immun 2002; 3: 259.
  • 8
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 9
    Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 10
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 11
    Smolen J, Breedveld F, Burmester G, Combe B, Emery P, Kalden J, et al. Consensus statement on the initiation and continuation of TNF blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 5045.
  • 12
    Louis E, Vermeire S, Rutgeerts P, De Vos M, van Gossum A, Pescatore P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with −308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 81824.
  • 13
    Lacki J, Moser R, Korczowska I, Mackiewicz S, Muller W. TNF-alpha gene polymorphism does not affect the clinical and radiological outcome of rheumatoid arthritis. Rheumatol Int 2000; 19: 13740.
  • 14
    Brinkman B, Huizinga H, Kurban S, van der Velde E, Schreuder G, Hazes J, et al. Tumor necrosis factor α gene polymorphisms in rheumatoid arthritis: association with susceptibility to or severity of disease? Br J Rheumatol 1997; 36: 51621.
  • 15
    Jawaheer D, Li W, Graham R, Chen W, Damle A, Xiao X, et al. Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am J Hum Genet 2002; 71: 58594.